drugset / Trial / NCT05525910

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

NCT05525910

Phase 1 Completed 15 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to estimate the relative bioavailability of nirmatrelvir/ritonavir of 4 different FDC tablet formulations relative to the commercial tablet formulation under fasted conditions in healthy adult participants.

Timeline

Start
2022-08-31
Primary completion
2022-11-07
Completion
2022-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Nirmatrelvir Small molecule Oral
Subject Ritonavir Other / unclassified Oral

Indications

No indication recorded.